CytomX Therapeutics (CTMX) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' Consolidated Net Income fell 34806.49% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10258.86%. This contributed to the annual value of $31.9 million for FY2024, which is 570087.87% up from last year.
- Latest data reveals that CytomX Therapeutics reported Consolidated Net Income of -$14.2 million as of Q3 2025, which was down 34806.49% from -$154000.0 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Consolidated Net Income ranged from a high of $23.5 million in Q1 2025 and a low of -$34.8 million during Q4 2021
- Moreover, its 5-year median value for Consolidated Net Income was -$6.5 million (2024), whereas its average is -$9.2 million.
- Examining YoY changes over the last 5 years, CytomX Therapeutics' Consolidated Net Income showed a top increase of 215519.71% in 2024 and a maximum decrease of 50110.4% in 2024.
- Over the past 5 years, CytomX Therapeutics' Consolidated Net Income (Quarter) stood at -$34.8 million in 2021, then soared by 74.8% to -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then surged by 2155.2% to $18.9 million in 2024, then crashed by 175.38% to -$14.2 million in 2025.
- Its Consolidated Net Income was -$14.2 million in Q3 2025, compared to -$154000.0 in Q2 2025 and $23.5 million in Q1 2025.